未找到相关数据
Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure
被引：23
作者：
Demetri, G. D.
Huang, X.
Garrett, C. R.
Schoffski, P.
Blackstein, M. E.
Shah, M. H.
Verweij, J.
Tassell, V.
Baum, C. M.
Casali, P. G.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Pfizer Global Res & Dev, La Jolla, CA USA
[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[4] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[5] Univ Toronto, Toronto, ON, Canada
[6] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[7] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[8] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[9] Ist Nazl Tumori, I-20133 Milan, Italy
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.10524
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10524
引用
收藏
页数：1
相关论文